The new cuts affect approximately 25 of staff primarily those working on early stage programs and at a gene therapy facility in New Jersey. The layoffs follow a decision by European regulators to deny PTCs request to convert Translarnas conditional clearance there to a full approval for types of Duchenne muscular dystrophy